Beese Fulmer Investment Management Inc. Purchases New Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Beese Fulmer Investment Management Inc. acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,311 shares of the biopharmaceutical company’s stock, valued at approximately $213,000.

A number of other hedge funds also recently made changes to their positions in the business. Sumitomo Mitsui DS Asset Management Company Ltd lifted its position in shares of Gilead Sciences by 4.8% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 159,693 shares of the biopharmaceutical company’s stock worth $14,751,000 after buying an additional 7,295 shares during the period. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Gilead Sciences by 0.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,034,060 shares of the biopharmaceutical company’s stock worth $280,256,000 after purchasing an additional 10,076 shares in the last quarter. Strategic Financial Concepts LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $6,640,000. GHP Investment Advisors Inc. grew its stake in Gilead Sciences by 1.1% during the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 122 shares during the last quarter. Finally, Beacon Financial Advisory LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth approximately $206,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Down 1.6 %

NASDAQ:GILD opened at $98.04 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $100.51. The stock has a 50-day moving average price of $92.86 and a two-hundred day moving average price of $86.41. The stock has a market cap of $122.18 billion, a price-to-earnings ratio of 1,089.33, a PEG ratio of 1.37 and a beta of 0.18. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the business earned $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on GILD. Citigroup assumed coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price on the stock. Bank of America reissued a “buy” rating and issued a $109.00 price objective on shares of Gilead Sciences in a research note on Tuesday, December 10th. Sanford C. Bernstein started coverage on Gilead Sciences in a report on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price target for the company. JPMorgan Chase & Co. upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 29th. Finally, UBS Group boosted their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $98.39.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Jeffrey Bluestone sold 6,788 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the sale, the director now owns 8,920 shares in the company, valued at $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 572,824 shares of company stock valued at $53,611,715 over the last quarter. Corporate insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.